Mounjaro® providers &
prescriptions in Wilkes-Barre, PA
Mounjaro is FDA-approved for type 2 diabetes, not for weight management.[1] The tirzepatide approved for chronic weight management is Zepbound in Wilkes-Barre.
Physicians near Wilkes-Barre, PA from the federal NPI registry. Ask each office whether it prescribes Mounjaro.[9]
Same molecule (tirzepatide): Tirzepatide in Wilkes-Barre, Zepbound in Wilkes-Barre
Other GLP-1 medicines: Ozempic in Wilkes-Barre, Wegovy in Wilkes-Barre, Semaglutide in Wilkes-Barre
Find a Mounjaro provider in Wilkes-Barre.
Every entry comes from the federal NPI registry. Ask each office what it prescribes. We do not accept payment for placement.
How to get Mounjaro in Wilkes-Barre.
13 GLP-1 prescribers and 6 local resource types are on record for Wilkes-Barre, plus 3 nearby towns in the directory.
Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Pennsylvania’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.
An injectable medication for adults with type 2 diabetes. Same molecule as Zepbound.
Mounjaro is the brand name Eli Lilly uses for tirzepatide approved for type 2 diabetes. It is a once-weekly subcutaneous injection and the first approved dual GIP/GLP-1 receptor agonist. It activates two gut-hormone pathways rather than one. The identical molecule, marketed as Zepbound, is the FDA-approved formulation for chronic weight management.[2][3]
In the SURPASS-2 head-to-head trial, tirzepatide produced greater HbA1c reductions and greater weight loss than semaglutide 1 mg across all doses. Across the SURPASS program, tirzepatide lowered HbA1c by approximately 1.8 to 2.6 percentage points. Mounjaro is approved as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes.[1]
Community health · CDC
Weight & metabolic health in Wilkes-Barre
Wilkes-Barre, Pennsylvania has a population of 44,328 people. The adult obesity rate in Wilkes-Barre is an age-adjusted estimate of 42.6%, 8.4 percentage points above the Pennsylvania state rate of 34.2%. Diagnosed diabetes reaches 12.6% of adults in Wilkes-Barre. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 32.2% of adults in Wilkes-Barre.
- of Wilkes-Barre adults have obesity
- 42.6%
- diagnosed diabetes
- 12.6%
- no regular physical activity
- 32.2%
Age-adjusted estimates for Wilkes-Barre, community figures, not individual risk. CDC PLACES, 2024 release.
The prescription is one part. Here is the rest, in Wilkes-Barre.
Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near Wilkes-Barre, PA, ordered as the registry lists them, never by who pays us.
Registered dietitians
A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.
640 Madison Ave
175 South Wilkes-Barre Blvd.
Gyms near you
A gym gives you the regular movement that keeps muscle while the weight comes off.
What the trials actually showed.
We summarize the SURPASS diabetes program, including the SURPASS-2 head-to-head against semaglutide. Figures are means at each trial's primary endpoint.
Most Mounjaro side effects are stomach and gut effects.
In Mounjaro's diabetes trials at 5 to 15 mg, the most common side effects were nausea (12 to 18%), diarrhea (12 to 17%), decreased appetite (5 to 11%), and vomiting (5 to 9%). Most reports came during dose escalation and decreased over time.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[1]
What Mounjaro costs, by how you pay.
The price you pay depends on your insurance plan, your diagnosis, and how you buy. Manufacturer self-pay programs cost far less than pharmacy retail. Here are the ranges.
Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Eli Lilly self-pay and savings pages.
Self-pay and savings card prices checked . Retail averages from May 2026.
| Pharmacy retail (no insurance) | $1,000 to $1,200 | per month | Brand-name retail average, May 2026[6] |
|---|---|---|---|
| LillyDirect self-pay | from $499 | per month | Listed at the same starting price for every strength, 2.5 mg to 15 mg |
| Commercial insurance (T2D) | $25 to $250 | per month copay | Usually covered for diabetes with prior authorization |
| Medicare Part D | $0 to $100 | per month | T2D covered; weight-loss indication not covered by law[5] |
| Manufacturer savings card | as low as $25 | per month | Commercial insurance only; eligibility limits apply |
Physicians from the federal NPI registry. Ask each office whether it prescribes Mounjaro.
Physicians from the federal NPI registry in the states we cover. Ask each office whether it prescribes Mounjaro.
The questions people ask before they book.
Answers reviewed by the glp·helper Medical Team. Citations link to primary sources, never marketing copy.
Mounjaro and Zepbound are both tirzepatide, made by Eli Lilly, but they carry different FDA-approved indications. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. Insurers treat them as separate products, and coverage differs sharply between the two.[1]
In the SURPASS-2 head-to-head diabetes trial, tirzepatide produced greater HbA1c reductions and greater weight loss than semaglutide 1 mg across all doses. The two have not been compared head-to-head at their maximum weight-management doses, so direct weight-loss superiority outside diabetes is inferred rather than proven.[3]
Yes. Mounjaro is a prescription-only medicine, marked Rx only on its label. A licensed prescriber (MD, DO, NP, or PA) must evaluate you before issuing a prescription.[1]
For type 2 diabetes, most commercial plans cover Mounjaro with prior authorization, and Medicare Part D covers it for T2D. It is not covered for weight loss alone. Zepbound is the on-label option for obesity but is itself frequently restricted.[5]
In most states, yes. Telehealth prescribing is permitted once a practitioner-patient relationship is established, typically via a synchronous video visit, by a provider licensed in your state.[1]